Potassium-sparing diuretics are a class of medications that help your body shed excess fluid and sodium while holding on to potassium, a mineral most other diuretics flush out. They work in the last stretch of the kidney’s filtering system, and they come in two distinct families that achieve this goal through entirely different mechanisms. Though they are mild diuretics on their own, their real clinical value lies in heart failure, liver disease, resistant high blood pressure, and a growing list of uses that have little to do with fluid balance at all.
Two Families, Two Mechanisms
Potassium-sparing diuretics split neatly into two groups based on how they prevent potassium loss. The first group blocks the hormone aldosterone from doing its job. Aldosterone normally tells cells in the kidney’s collecting duct to pull sodium back into the bloodstream and push potassium out into the urine. Spironolactone and eplerenone are the best-known aldosterone blockers (formally called mineralocorticoid receptor antagonists, or MRAs). By occupying the receptor that aldosterone binds to, they reduce sodium reabsorption and, as a side effect, keep potassium from being secreted.
The second group skips aldosterone entirely and goes straight to the sodium channel itself, called the epithelial sodium channel, or ENaC. Amiloride and triamterene physically plug this channel so sodium cannot pass through. Research on triamterene has shown that it binds within the channel in a voltage-dependent and pH-dependent way, acting as a positively charged molecule that lodges inside the pore.1PubMed. Blockade of epithelial Na+ channels by triamterenes – underlying mechanisms and molecular basis The practical result is the same: less sodium gets reabsorbed, less potassium gets lost. But the distinction matters for side effects, drug interactions, and the conditions each group treats best.
Why They Are Rarely Used Alone for Blood Pressure
On their own, potassium-sparing diuretics are weak blood-pressure-lowering agents. The amount of sodium they block in the collecting duct is small compared with what thiazide or loop diuretics block farther upstream. For this reason, you will almost always see amiloride or triamterene packaged in a fixed-dose pill alongside hydrochlorothiazide rather than prescribed solo.
That combination turns out to be more than the sum of its parts. A systematic review and network meta-analysis of randomized trials found that thiazides combined with a potassium-sparing diuretic lowered blood pressure more effectively than thiazides alone, while also reducing the risk of low potassium and high blood sugar, two common thiazide side effects.2PubMed Central. Thiazide diuretics alone or combined with potassium-sparing diuretics to treat hypertension: a systematic review and network meta-analysis of randomized controlled trials The potassium-sparing agent essentially cleans up the metabolic mess that the thiazide creates. It also reduces the risk of magnesium depletion and the dangerous heart rhythms that can follow.3PubMed. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents
One older review pushed back on the idea that every patient on a thiazide needs a potassium-sparing partner, arguing that the small drop in potassium caused by low-dose thiazides rarely causes clinical problems in patients who are not also taking digoxin. The routine prophylactic use of potassium-sparing diuretics alongside thiazides, that review concluded, is not always justified. In practice, many clinicians still add one when patients develop low potassium or when the patient is on digoxin, where even mild potassium drops raise the risk of toxicity.4PubMed. Potassium-sparing diuretics: interaction with digoxin in elderly men
Heart Failure Changed the Conversation
The story of potassium-sparing diuretics in heart failure is largely the story of spironolactone and the landmark trial that put it on the map. In 1999, the Randomized Aldactone Evaluation Study (RALES) enrolled patients with severe heart failure and found that adding a low dose of spironolactone to standard treatment cut the risk of death by 30 percent. Deaths from worsening heart failure and sudden cardiac death both dropped, and hospitalizations for heart failure fell by 35 percent.5PubMed. The effect of spironolactone on morbidity and mortality in patients with severe heart failure These were not small, ambiguous effects. The trial was stopped early because the benefit was so clear.
What made these results surprising at the time was the realization that spironolactone was not just adjusting fluid balance. Aldosterone, it turned out, does damage far beyond the kidney. It promotes scarring (fibrosis) in the heart muscle, stiffens blood vessels, and drives inflammation. Blocking it reverses some of that damage, which is why MRAs improve heart function beyond what you would expect from a mild diuretic. A meta-analysis comparing eplerenone and spironolactone in heart failure with reduced ejection fraction confirmed that both agents improve the heart’s pumping efficiency, though eplerenone is more selective for the mineralocorticoid receptor and tends to cause fewer hormonal side effects.6Mayo Clinic Proceedings. Eplerenone versus Spironolactone and Cardiac Remodeling in Heart Failure with Reduced Ejection Fraction: A Meta-Analysis
The Go-To Drug for Liver Cirrhosis Ascites
When the liver becomes severely scarred, fluid accumulates in the abdomen, a condition called ascites. The failing liver signals the kidneys to retain sodium aggressively, and aldosterone levels climb because the damaged liver can no longer break the hormone down. This makes spironolactone a natural fit. Guidelines recommend it as the first-choice diuretic for mild to moderate ascites, with furosemide (a loop diuretic) added only when spironolactone alone is not enough.7PubMed Central. Diagnosis and therapy of ascites in liver cirrhosis
Eplerenone works just as well for controlling the fluid, and a comparative study in cirrhosis patients found that its side-effect profile is better than spironolactone’s, which matters when patients already feel terrible and are sensitive to additional symptoms.8PubMed. Comparative study of spironolactone and eplerenone in management of ascites in patients of cirrhosis of liver Cost and availability still favor spironolactone in most settings, so eplerenone tends to be reserved for patients who cannot tolerate it.
Resistant Hypertension and the Aldosterone Connection
Some people’s blood pressure refuses to come down despite taking three or more medications at adequate doses. This is called resistant hypertension, and a surprisingly common culprit is excess aldosterone, even in patients who do not have a formal aldosterone-producing tumor. In these cases, spironolactone at doses between 25 and 50 mg per day can produce dramatic drops in blood pressure. Clinical guidance identifies MRAs as especially effective in low-renin and salt-sensitive forms of hypertension, which describes many patients with resistant disease. When spironolactone is not tolerated because of its hormonal side effects, eplerenone serves as an alternative.
The Hyperkalemia Question
The most talked-about risk with every potassium-sparing diuretic is high potassium, or hyperkalemia. The whole point of these drugs is to keep potassium from leaving the body, so pushing the level too high is an inherent possibility. Potassium levels that climb too far can cause dangerous heart-rhythm problems.
The risk is not evenly distributed. A large nested case-control study in patients with newly diagnosed heart failure identified current use of potassium-sparing diuretics as one of the strongest predictors of hyperkalemia, roughly tripling the odds. Kidney failure, type 2 diabetes, and concurrent use of ACE inhibitors or the antibiotic trimethoprim also raised the risk substantially. The danger was highest within the first month of starting the medication and tapered off afterward.9European Journal of Heart Failure. Risk Factors for Hyperkalaemia in a Cohort of Patients with Newly Diagnosed Heart Failure: A Nested Case–Control Study in UK General Practice The broader pathophysiology is straightforward: anything that limits the kidney’s ability to dump potassium, whether reduced kidney function, diabetes, or drugs that suppress aldosterone, stacks the deck toward hyperkalemia.10Nephrology Dialysis Transplantation. Hyperkalemia: pathophysiology, risk factors and consequences
Yet the picture is not as alarming as it might seem for everyone. A U.S. cohort study using electronic health records compared patients taking potassium-sparing diuretics alone or with an ACE inhibitor or ARB against a control group. The average increase in serum potassium was only about 0.07 to 0.10 mmol/L, a shift the authors characterized as unlikely to be clinically meaningful. There were no significant differences in the odds of developing outright hyperkalemia across the groups.11JAPhA Pharmacotherapy. Changes in serum potassium with concomitant administration of renin-angiotensin system agents and potassium-sparing diuretics: U.S. cohort study using electronic health record data The takeaway: hyperkalemia risk is real and worth monitoring, but it concentrates in people who already have compromised kidney function, diabetes, or several potassium-raising medications stacked together. A healthy person on a single potassium-sparing diuretic for blood pressure is at much lower risk.
Spironolactone’s Hormonal Side Effects
Spironolactone does not limit itself to blocking aldosterone. Its chemical structure also lets it interfere with androgen receptors and, to a lesser degree, interact with progesterone receptors. In men, this can lead to breast tenderness and breast tissue enlargement, a condition called gynecomastia. The mechanism involves blocking androgen production, preventing androgens from binding to their receptors, and raising levels of both total and free estrogen.12Quality in Sport. Current state of knowledge about spironolactone-induded gynecomastia. Review 2024 This is dose-dependent and more common at the higher doses used for cirrhosis or heart failure than at the 25 mg doses used for resistant hypertension.
Eplerenone was developed specifically to avoid this problem. It binds more tightly to the mineralocorticoid receptor and has far less affinity for androgen and progesterone receptors. For men who develop gynecomastia or sexual side effects on spironolactone, switching to eplerenone often resolves the issue while preserving the cardiac or blood-pressure benefit.
Uses That Have Nothing to Do with Fluid Balance
Spironolactone’s anti-androgen properties are a side effect in cardiac patients but a feature in others. Dermatologists prescribe it off-label for hormonal acne and excess hair growth (hirsutism) in women, particularly those with polycystic ovary syndrome (PCOS). By dampening androgen signaling, spironolactone reduces the oil production that feeds acne and slows hair growth in androgen-sensitive areas. A study in women with PCOS found that spironolactone treatment significantly lowered clinical hirsutism scores in both lean and overweight participants, and most women with acne at baseline saw improvement.13PubMed Central. Efficacy of Spironolactone in Adult Acne in Polycystic Ovary Syndrome Patients an Original Research In these uses, the diuretic effect is barely relevant; patients are taking the drug purely for its hormonal action.
Amiloride and triamterene have their own niche application in Liddle’s syndrome, a rare inherited form of high blood pressure caused by overactive ENaC channels. Because the defect is in the channel itself, aldosterone blockers do not help. But amiloride and triamterene, which directly plug that channel, can normalize blood pressure and correct the electrolyte imbalance when combined with a low-sodium diet.14PubMed Central. Liddle’s syndrome mechanisms, diagnosis and management It is a textbook example of matching the drug to the molecular defect.
Finerenone and the Newer Generation
The newest member of the MRA family is finerenone, a nonsteroidal mineralocorticoid receptor antagonist. Unlike spironolactone and eplerenone, which are built on a steroid backbone, finerenone has a completely different chemical structure. This gives it a more balanced distribution between the heart and the kidneys and avoids the steroid-related side effects.
Finerenone’s big claim to fame is protecting the kidneys in people with type 2 diabetes and chronic kidney disease. In a trial with a median follow-up of about two and a half years, finerenone reduced the composite kidney outcome (a cluster of kidney failure, sustained large drops in filtration rate, or kidney-related death) compared with placebo. Roughly 18 percent of patients on finerenone experienced a primary endpoint event, versus 21 percent on placebo.15PubMed. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes A pooled analysis of two large finerenone trials confirmed the kidney benefit: the composite kidney outcome occurred in about 5.5 percent of finerenone patients versus 7.1 percent on placebo, with a number needed to treat of 60 over three years.16European Heart Journal. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
This matters because diabetic kidney disease is one of the leading causes of kidney failure worldwide, and treatment options that slow its progression are limited. Finerenone adds to the toolkit alongside ACE inhibitors, ARBs, and the newer SGLT2 inhibitors. It still carries a risk of hyperkalemia, but rates in the trials were manageable with routine monitoring.
How MRAs May Protect Kidneys Beyond Fluid Control
The kidney-protective effects of aldosterone blockers appear to go beyond simply reducing blood pressure or fluid volume. A randomized, placebo-controlled trial of eplerenone in patients with chronic kidney disease found that kidney filtration rate initially dipped in the first six months of treatment, then stabilized. Over 36 months, the annual decline in filtration was roughly a third the rate seen in the placebo group.17Scientific Reports. The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial That early dip is thought to reflect the correction of aldosterone-driven hyperfiltration, a state where the kidney works harder than it should, which looks good on lab tests in the short term but accelerates damage over time. Once that excessive filtration pressure is relieved, proteinuria drops and the kidney’s long-term trajectory improves.18Hypertension Research. Does the temporary decrease in the estimated glomerular filtration rate (eGFR) after initiation of mineralocorticoid receptor (MR) antagonist treatment lead to a long-term renal protective effect?
Clinicians who see a patient’s kidney numbers dip shortly after starting an MRA sometimes get nervous and stop the drug. Understanding that this early dip is expected and actually signals a protective hemodynamic shift can prevent premature discontinuation of a therapy that pays off over months and years.
Amiloride Versus Triamterene
Among the ENaC blockers, amiloride and triamterene are often treated as interchangeable, but they are not identical. A head-to-head comparison found that amiloride combined with hydrochlorothiazide increased renal prostaglandin E2 production, while triamterene combined with the same thiazide actually decreased it.19PubMed. Antihypertensive therapy with triamterene-hydrochlorothiazide vs amiloride-hydrochlorothiazide. Comparison of effects on urinary prostaglandin E2 excretion Prostaglandins in the kidney help maintain blood flow and support the action of diuretics, so this difference could matter for how well each combination works in practice and how it affects the kidney over time.
Triamterene has also been linked, rarely, to kidney stone formation because it can crystallize in the urine. Amiloride does not share this problem. For most patients the distinction is academic since both drugs are well tolerated at standard doses, but when a patient has a history of kidney stones, amiloride is the safer pick.
Children and Cardiac Intensive Care
You might expect spironolactone to reduce the need for intravenous potassium replacement in children recovering from heart surgery, where loop diuretics are used aggressively and potassium drops fast. But a study in a pediatric cardiac intensive care unit found that adding spironolactone did not reduce the amount of potassium supplementation needed, and there was no measurable difference in rates of low or high potassium between children who received spironolactone and those who did not.20PubMed. Spironolactone effect on potassium supplementation in paediatric cardiac intensive care patients The authors suggested that the routine use of spironolactone in this particular setting may not be more helpful than simply giving potassium directly. This is a useful reminder that findings from adult heart failure trials do not always translate to every clinical scenario, and the benefit of potassium-sparing diuretics depends heavily on context.